Back to Search
Start Over
Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome.
- Source :
-
Leukemia & lymphoma [Leuk Lymphoma] 2022 Aug; Vol. 63 (8), pp. 1831-1838. Date of Electronic Publication: 2022 Mar 09. - Publication Year :
- 2022
-
Abstract
- Venetoclax is a BCL-2 inhibitor approved for treatment of adult patients with chronic lymphocytic leukemia (CLL). Due to significant risk of tumor lysis syndrome (TLS) upon treatment initiation, a 5-week dose ramp-up is recommended. University of North Carolina Medical Center (UNCMC) utilizes a novel interdisciplinary model of care involving clinical pharmacists (CPs) who oversee the 5-week ramp-up to minimize treatment-related adverse events. The aim of this study was to investigate the effects of a pharmacist-led venetoclax initiation protocol on patient outcomes. The primary objective was to determine the incidence of venetoclax-induced TLS during dose ramp-up in patients managed by a CP. In this cohort ( n = 39), there were no cases of TLS during the venetoclax ramp-up. Reduced TLS rates were observed in CP-managed real-world patients compared to previous real-world reports. This real-world analysis supports the utilization of CPs for intensive monitoring of patients initiated on venetoclax.
- Subjects :
- Adult
Antineoplastic Combined Chemotherapy Protocols adverse effects
Bridged Bicyclo Compounds, Heterocyclic adverse effects
Humans
Sulfonamides adverse effects
Antineoplastic Agents adverse effects
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Tumor Lysis Syndrome diagnosis
Tumor Lysis Syndrome etiology
Tumor Lysis Syndrome prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 1029-2403
- Volume :
- 63
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Leukemia & lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 35262457
- Full Text :
- https://doi.org/10.1080/10428194.2022.2047963